Advertisement
Organisation › Details
Neogap Therapeutics AB
NEOGAP Therapeutics is a Swedish biotechnology company focused on developing personalised cancer immunotherapy using the patient’s cells. The therapy is based on the company’s two technologies, PIOR® and EpiTCer®. PIOR® is sophisticated software that uses DNA sequencing data from the patient and machine learning algorithms to select tumour-specific mutations. Then, EpiTCer® is used to multiply T cells that can recognise and attack the selected tumour-specific targets. NEOGAP is located at the Center for Molecular Medicine at the Karolinska Institute in Stockholm. *
Start | 2016-01-01 established | |
Industry | EpiTCer® technology | |
Industry 2 | bioinformatics (biological software and databases) | |
Person | Svensson, Samuel (Neogap Therapeutics 202305 CEO) | |
Region | Stockholm | |
Country | Sweden | |
Street | Karolinska Universitetssjukhuset Center for Molecular Medicine | |
City | 17176 Stockholm | |
Tel | +46-733-542194 | |
Address record changed: 2023-05-07 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Neogap Therapeutics AB. (5/4/23). "Press Release: Neogap and Cellerys Enter Collaboration Related to Phase II Study of a New Therapy for Multiple Sclerosis". | ||
Record changed: 2024-02-12 |
Advertisement
More documents for Neogap Therapeutics AB
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top